Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Study: Abbott's Depakote Ingredient Linked to Autism
- A small study has found a correlation between pregnant epileptic women who took the active ingredient in Depakote (Epilim in the U.K.) and autism in their children. The study will be published in the journal Neurology no link yet. Here's the meat of it: The study ... followed 632...
- Blog posts 2008-12-04
Additional Resources
- Abbott under kickback probe over Depakote sales -
- Abbott Laboratories this morning confirmed the company's sales and marketing practices of Depakote, the widely used drug to treat bipolar disorder and epilepsy, are under federal investigation. The U.S. Department of Justice , through the U.S. Attorney for the Western District of Virginia...
- News items 2009-11-06
- Abbott Laboratories' Depakote — divalproex sodium — now indicated for prevention of migraine headaches
- ABBOTT PARK, Ill.--HealthWire--March 28, 1996--Abbott Laboratories' DepakoteR divalproex sodium tablets have been cleared by the U.S. Food and Drug Administration for the prevention of migraine headaches. The entry of Depakote into the marketplace represents a new prophylactic treatment option for migraine headache sufferers.
- Research articles 1996-03-28
- Abbott Laboratories Q3 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator Instructions. Our first question today is from Glenn Reicin. And please state your company name. Glenn Reicin - Morgan Stanley All right. Good morning, folks. Glenn Reicin, Morgan Stanley. John Thomas Hi, Glenn. Tom Freyman Hi, Glenn. Glenn Reicin - Morgan Stanley Lot of...
- Earnings calls 2007-10-17
- Abbott Labs' "Position of Strength" May Not Be as Strong as It Looks
- Figuring out whether Abbott Laboratories is firing on all cylinders or heading for a wall is a complicated business. On the one hand, the company announced it would lay off 1,000 employees in its diagnostics business. Abbott spokesperson Melissa Brotz said: We are taking this action...
- Blog posts 2008-08-26
- Abbott Laboratories Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Our first question today is from Mike Weinstein. And please state your company name. Mike Weinstein - J.P. Morgan Thank you. It's J.P. Morgan. Excuse me, a couple questions if we could start-off. There was during this quarter, there was that Barron's article and there...
- Earnings calls 2007-07-18
- Active pharmaceutical ingredient watch. (Markets: Life Sciences).(pharmaceutical industry; news briefs)(Brief Article)
- APOTEX Corp. moved closer to marketing a generic version ofAbbott Laboratories bipolar disorder drug Depakote divalproex sodium. The company says a federal appeals court reversed a summary judgement granted by a district court in Abbott's patent infringement lawsuit. The patent on Depakote expires in 2008. Banc...
- Research articles 2002-09-02
- Abbott Laboratories Q1 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Your first question comes from Rick Wise from Leerink Swann. Frederick Wise - Leerink Swann Llc Let me start off with a big picture question since we have the pleasure of Miles on the call again. Miles...
- Earnings calls 2009-04-17
- Abbott Labs' Secret Weapon: Layoffs
- Sometimes a company does everything right and no one notices: Abbott Labs just unveiled a stellar third quarter and investors shrugged, leaving its stock flat. The basics you already know: Profit up 51 percent to $1.08 billion, sales up 17.6 percent to $7.5 billion. But check out...
- Blog posts 2008-10-15
- PharMerica Corporation Q3 2008 Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions. And the first question comes from the line of Adam Feinstein from Barclays Capital. Please proceed. Adam Feinstein - Barclays Capital Alright, thank you very much. Good morning everyone, very strong quarter. Just wanted to just ask few questions here, I guess it seems...
- Earnings calls 2008-10-31
- Abbott Labs Q1: Has the Company Taken Its Eye Off the Sales Force Ball?
- Abbott Labs' stock took a beating today even though it posted a 53 percent gain in net income, to $1.4 billion. Investors didn't like that $1 billion of that profit came from a one-off item reflecting the end of a joint venture with TAP. Revenues were flat at $6.7 billion....
- Blog posts 2009-04-15
- Mylan Inc. Q1 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator instructions. Our first question is from Randall Stanicky with Goldman Sachs. Randall Stanicky – Goldman Sachs Great. Thanks for the question. Just a two-part question. First Robert, can you just talk about 2010 outlook, are you still comfortable with that range, and are the...
- Earnings calls 2009-05-01
- Earnings Preview: Abbott Labs
- Abbott Labs ABT is expected to report Q2 earnings Wednesday, July 15 before market open, with a conference call scheduled for 9:00 am ET. Guidance Analysts are looking for EPS of 89c on revenue of $7.55B. The consensus range is 87c-90c for EPS, and $7.31B-$7.85B for revenue, according to...
- External links 2009-07-14
- Abbott Profit Up on Humira Demand, Special Gain
- By Ransdell Pierson and Lewis KrauskopfNEW YORK (Reuters) - Abbott Laboratories Inc ABT said its third-quarter profit rose 37 percent on strong demand for its Humira arthritis drug and nutritional products, as well as gains from a settlement with Medtronic Inc MDT.The profit reported on Wednesday topped Wall Street forecasts,...
- News items 2009-10-14
- Abbott Profit Up on Humira Demand, Special Gain
- By Ransdell Pierson and Lewis Krauskopf NEW YORK (Reuters) - Abbott Laboratories Inc ABT said its third-quarter profit rose 37 percent on strong demand for its Humira arthritis drug and nutritional products, as well as gains from a settlement with Medtronic Inc MDT. The profit reported on Wednesday topped Wall...
- News items 2009-10-14
- Earnings Preview: Mylan
- Mylan MYL is expected to report Q3 earnings on Thursday, October 29, before the market open, with a conference call scheduled for 10 am ET. Guidance Analysts are looking for EPS of 27c on revenue of $1.23B. The consensus range is 24c-31c for EPS, and $1.18B-$1.28B...
- External links 2009-10-28
- Analyst face-off: Abbott Labs
- NEW YORK Fortune -- Shares of Abbott Laboratories stabilized Tuesday after dropping more than 2% in the previous session when it said it would buy the industry's biggest Lasik vision equipment maker for $2.8 billion. Over the past few years, investors have cheered on Abbott, a $26 billion health care...
- News items 2009-08-07
- << Previous
- page 1 of 1
- Next >>
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
